JA
Unclaimed author profile

Janet L Leasher

· Nova Southeastern University

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim
2Linked publications
0Citations
0h-index
0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Janet L Leasher is a registered researcher in their academic field.

Research output

Recent Publications

2 research works linked to this profile

▤
Ophthalmology and Visual Impairment Studies, Tactile and Sensory Interactions, Retinopathy of Prematurity Studies · 2020 · The Lancet Global Health

Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study

Rupert Bourne, Jaimie D Steinmetz, Seth Flaxman, Paul Svitil Briant, Hugh R. Taylor, Serge Resnikoff, Robert J. Casson, Amir Abdoli, Eman Abu‐Gharbieh, Ashkan Afshin, Hamid Ahmadieh, Yonas Akalu, Alehegn Aderaw Alamneh, Wondu Alemayehu, Ahmed Samir Alfaar, Vahid Alipour, Etsay Woldu Anbesu, Sofia Androudi, Jalal Arabloo, Aries Arditi, Malke Asaad, Eleni Bagli, Atif Amin Baig, Till Bärnighausen, Maurízio Battaglia Parodi, Akshaya Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, Krittika Bhattacharyya, Ali Bijani, Mukharram M. Bikbov, Michele Bottone, Tasanee Braithwaite, Alain M. Bron, Zahid A Butt, Ching‐Yu Cheng, Dinh‐Toi Chu, Maria Vittoria Cicinelli, João Coelho, Baye Dagnew, Xiaochen Dai, Reza Dana, Lalit Dandona, Rakhi Dandona, Monte A. Del Monte, Jenny P Deva, Daniel Díaz, Shirin Djalalinia, Laura E. Dreer, Joshua R. Ehrlich, Leon B. Ellwein, Mohammad Hassan Emamian, Arthur Gustavo Fernandes, Florian Fischer, David S. Friedman, João M. Furtado, Abhay Gaidhane, Shilpa Gaidhane, Gus Gazzard, Berhe Gebremichael, Ronnie George, Ahmad Ghashghaee, Mahaveer Golechha, Samer Hamidi, Billy R. Hammond, M. Elizabeth Hartnett, Risky Kusuma Hartono, Simon I Hay, Golnaz Heidari, Hung Chak Ho, Chi Linh Hoang, Mowafa Househ, Segun Emmanuel Ibitoye, Irena Ilić, Milena Ilić, April Ingram, Seyed Sina Naghibi Irvani, Ravi Prakash Jha, Rim Kahloun, Himal Kandel, Ayele Semachew Kasa, John H. Kempen, Maryam Keramati, Moncef Khairallah, Ejaz Ahmad Khan, Rohit C Khanna, Mahalaqua Nazli Khatib, Judy E. Kim, Yun Jin Kim, Sezer Kısa, Adnan Kısa, Ai Koyanagi, Om Kurmi, Van Charles Lansingh, Janet L Leasher, Nicolas Leveziel, Hans Limburg, Marek Majdán, Navid Manafi, Kaweh Mansouri

Background To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990–2020, and forecasts for 2050. Methods We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and

▤
Global Cancer Incidence and Screening, Cancer Risks and Factors, Multiple and Secondary Primary Cancers · 2015 · JAMA Oncology

The Global Burden of Cancer 2013

Christina Fitzmaurice, Daniel Dicker, Amanda Pain, Hannah Hamavid, Maziar Moradi‐Lakeh, Michael F MacIntyre, Christine A. Allen, Gillian M Hansen, Rachel Woodbrook, Charles Wolfe, Randah R Hamadeh, Ami R. Moore, Andrea Werdecker, Bradford D. Gessner, Braden Te Ao, Brian J. McMahon, Chanté Karimkhani, Chuanhua Yu, Graham Cooke, David C. Schwebel, David O. Carpenter, David M. Pereira, Denis Nash, Dhruv S Kazi, Diego De Leo, Dietrich Plaß, Kingsley Nnanna Ukwaja, George D. Thurston, Kim Yun Jin, Edgar P. Simard, Edward J Mills, Eun‐Kee Park, Ferrán Catalá-López, Gabrielle deVeber, Carolyn Gotay, Gulfaraz Khan, Hung Chak Ho, Itamar S Santos, Janet L Leasher, Jasvinder A. Singh, James Leigh, Jost B. Jonas, Juan Sanabria, Justin Beardsley, Kathryn H. Jacobsen, Ken Takahashi, Richard C. Franklin, Luca Ronfani, Marcella Montico, Luigi Naldi, Marcello Tonelli, Johanna M. Geleijnse, Max Petzold, Mark G. Shrime, Mustafa Z Younis, Naohiro Yonemoto, Nicholas J. K. Breitborde, Paul Yip, Farshad Pourmalek, Paulo A. Lotufo, Alireza Esteghamati, Graeme J. Hankey, Raghib Ali, Raimundas Lunevičius, Reza Malekzadeh, Robert P Dellavalle, Robert Weintraub, Robyn Lucas, Roderick J. Hay, David Rojas‐Rueda, Ronny Westerman, Sadaf G Sepanlou, Sandra Nolte, Scott B. Patten, Scott Weichenthal, Semaw Ferede Abera, Seyed-Mohammad Fereshtehnejad, Ivy Shiue, Tim Driscoll, Tommi Vasankari, Ubai Alsharif, Vafa Rahimi‐Movaghar, Vasily Vlassov, Wagner Marcenes, Wubegzier Mekonnen, Yohannes Adama Melaku, Yuichiro Yano, Al Artaman, Ismael Campos‐Nonato, Jennifer H MacLachlan, Ulrich Müeller, Daniel Kim, Matias Trillini, Babak Eshrati, Hywel C Williams, Kenji Shibuya, Rakhi Dandona, Kinnari Murthy, Benjamin Cowie, Azmeraw T. Amare

IMPORTANCE: Cancer is among the leading causes of death worldwide. Current estimates of cancer burden in individual countries and regions are necessary to inform local cancer control strategies. OBJECTIVE: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex from 1990 to 2013. EVIDENCE REVIEW: The general methodology of the Global Burden of Disease (GBD) 2013 study was used. Cancer registries were the source for cancer incidence data as well as mortality incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal autopsy studies, and other sources. The MI ratios were used to transform incidence data to mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying prevalence estimates with disability weights, which were derived from population-based surveys; YLLs were computed by multiplying the number of estimated cancer deaths at each age with a reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs. FINDINGS: In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries. CONCLUSIONS AND RELEVANCE: Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.